To the Editor I appreciated the nice review of the current status and promise for the use of next-generation sequencing (NGS) in identifying actionable somatic and germline molecular abnormalities as breast cancer therapeutic targets. The authors^1(p262) conclude that “circulating tumor DNA analysis, once sensitive and broad enough” will enable the identification of these actionable abnormalities.

中文翻译：

---

当前与下一代乳腺癌测序相关的挑战

对于编辑，我赞赏对当前状态的良好回顾，并承诺使用下一代测序 (NGS) 将可操作的体细胞和种系分子异常确定为乳腺癌治疗靶点。作者^{1 (p262)}得出结论，“循环肿瘤 DNA 分析，一旦足够敏感和广泛”将能够识别这些可操作的异常。